Nektar Therapeutics Q3 2026 net loss widens 57% to $55.65 million
NKTR•Nektar Therapeutics' third-quarter 2026 net loss widened 57% to $55.65 million, while revenue fell 20% to $9.39 million. Cash and marketable securities investments totaled $952.9 million at September 30.
1. Quarterly results
Nektar Therapeutics reported a third-quarter 2026 net loss of $55.65 million, up 57%, as revenue fell 20% to $9.39 million. Research and development expenses rose 62% to $44.12 million, primarily due to Phase 3 program support and rezpegaldesleukin manufacturing activities. Cash and marketable securities investments were $952.9 million at September 30, more than triple the December 31, 2025, balance.
2. Clinical program timeline
All three Phase 3 ZENITH AD trials have started, and the ZENITH AA trial is scheduled to begin in December 2026. Initial ZENITH AD topline data are expected in mid-2028, with a BLA submission targeted for 2029.
